site stats

Cisplatin resistance and pd-l1

WebApr 14, 2024 · Autophagy Influences Hypoxia, Chemoresistance, and Stem-like Phenotype in Breast Cancer It is known that cancer stem cells are a significant contributor to the development of chemoresistance in breast cancer [ 88, 89, 90, 91 ]. Autophagy enables the survival of CSCs under hypoxia in the tumor microenvironment [ 92 ]. WebApr 14, 2024 · Hypoxia also upregulates the expression of PD-1 ligand 1 (PD-L1) on MDSCs, macrophages, dendritic cells, ... Guo Q et al (2024) Hypoxia exposure induced cisplatin resistance partially via activating p53 and hypoxia inducible factor-1α in non-small cell lung cancer A549 cells. Oncol Lett 16:801–808.

Comparative study of the PD-L1 expression and CD8+ tumor …

WebCisplatin may also cause upregulation of tumor cell PD-L1, which may in part explain the additive antitumor activity of cisplatin and PD-L1/PD-1 blockade. This information will help in interpreting results of ongoing clinical trials combining these agents, and for comparison of potential future therapeutic combinations for the treatment of head ... WebMay 1, 2024 · Since PD-L1 expression protects tumor cells from pro-apoptotic drugs, we hypothesized that the PD-1/PD-L1 axis might contribute to the acquisition of resistance … simpletimer.h library download arduino https://americanffc.org

STING agonist therapy in combination with PD-1 immune ... - Nature

WebNov 4, 2024 · These 13 genes identify a variety of cisplatin-resistance mechanisms including increased transport and detoxification of cisplatin, and mis-regulation of the epithelial to mesenchymal transition. Conclusions We identified gene signatures in resistant TNBC subtypes indicative of mechanisms of cisplatin. WebNevertheless, the role of PD-L1 in chemoresistance development is not fully understood. In the current study, we aim to clarify the interaction of miR-519d-3p and PD-L1 in the development of cisplatin resistance. Immunohistochemistry, quantitative reverse-transcription polymerase reaction, and Western blot were used to evaluate PD-L1 … WebPatients were randomized (1:1:1) to receive one of the following treatments: pembrolizumab as a single agent; pembrolizumab, carboplatin or cisplatin, and FU; or cetuximab, carboplatin or ... simpletimer.h github

Cisplatin resistance: a cellular self-defense mechanism

Category:PD-1/PD-L1 enhanced cisplatin resistance in gastric cancer …

Tags:Cisplatin resistance and pd-l1

Cisplatin resistance and pd-l1

Analyses of single extracellular vesicles from non-small lung cancer ...

WebPD-L1 high expression was observed at prespecified expression levels of 5% of all cells in a section that included at least 100 evaluable tumor cells. 10 To evaluate the CD8+TIL … WebSep 18, 2024 · NCBI Bookshelf

Cisplatin resistance and pd-l1

Did you know?

WebNov 30, 2024 · Cisplatin may also cause upregulation of tumor cell PD-L1, which may in part explain the additive antitumor activity of cisplatin and PD-L1/PD-1 blockade. This … WebThe PD-L1 could reduce the level of cell damage caused by cisplatin. In addition, we found PD-L1 can also up-regulate the expression of P-gp. Mechanistically, PD-L1 activated the PI3K/AKT signaling pathway in which PI3K/AKT pathway inhibition attenuated the upregulation of P-gp.

WebDec 19, 2024 · The differential expression of PD-L1 at the mRNA and protein levels in the chemosensitive and chemoresistant cell lines strongly implicate PD-L1 in the development of cisplatin resistance.... http://mars.gmu.edu/handle/1920/13265?show=full

WebApr 14, 2024 · Moreover, subsequent experiments revealed that HAT1 upregulates PD-L1 expression through the action of the transcription factor BRD4, which binds to the promoter of PD-L1. ... Notably, during the development of cisplatin resistance, many changes at the genetic and epigenetic levels are evident . HAT1 has been shown to contribute to … WebThe interaction between programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) inhibits T-cell activation and proliferation. 4, 5 Several previous studies have reported that PD-L1 overexpression is a predictor of a poor clinical outcome in patients with NSCLC. 6 – 8 On the other hand, PD-L1 overexpression has been shown to be correlated with an …

http://mars.gmu.edu/handle/1920/13265?show=full

WebMay 28, 2024 · PD-L1 is critical for tumor cell escape from immune surveillance by inhibiting T cell function via the PD-1 receptor. Accumulating evidence demonstrates that anti-PD-L1 monoclonal antibodies might potently enhance antitumor effects in various tumors, but the effect of PD-L1 on colorectal cancer stem cells (CSCs) remains unclear. ray goodwin canoe outfittingray gopp victoria bcWebOct 22, 2024 · Cisplatin is an alkylating agent which induces DNA damage through the formation of cisplatin-DNA adducts, leading to cell cycle arrest and apoptosis. In the management of advanced OSCC, cisplatin-based chemotherapy or chemoradiotherapy has been considered as the first-line treatment. simple timer for light switchWeb14 hours ago · The results indicate that in contrast to erlotinib and cisplatin, osimertinib treatment increased a subset of the HER2 and PD-L1 positive EV population. However, the average expression of the two proteins on individual EVs was found to … ray goodrich elthamWebCisplatin is one of the most effective broad-spectrum anticancer drugs. Its effectiveness seems to be due to the unique properties of cisplatin, which enters cells via multiple … ray goodwin castle valeWebNov 15, 2024 · Abstract. Accumulating evidence indicates that a ligand of programmed cell death receptor-1 (PD-L1) participates in the progression and recurrence of multiple malignancies, including osteosarcoma. Nevertheless, the role of PD-L1 in chemoresistance development is not fully understood. simple timer in pythonWebImmune checkpoint blockade (ICB) with PD-1 or PD-L1 antibodies has been approved for the treatment of non–small cell lung cancer (NSCLC). However, only a minority of patients respond, and sustained remissions are rare. Both chemotherapy and antiangiogenic drugs may improve the efficacy of ICB in mouse tumor models and patients with cancer. ray google scholar